

HCV Real-TM Qual new version

Handbook

Real Time Kit for the Qualitative detection of Hepatitis C Virus in human plasma

REF V1-100 FRT REF TV1-100 FRT

REF TV1-100 FRT C



Sacace™ HCV Real-TM Qual

New Version

INTRODUCTION


Hepatitis C virus (HCV) is a single-stranded RNA virus that belongs to the family Flaviviridae. In 1974 HCV was initially recognized as non-A, non-B hepatitis virus (NANBH) until 1989 when the etiologic agent was cloned. It is estimated by the World Health Organization that worldwide there are 170 million HCV-infected persons.

The primary mode of HCV transmission is the exposure to infected human blood via intravenous, drug use or unscreened transfusions. Nosocomial HCV transmission during dialysis, colonoscopy, and surgery has also been reported. Perinatal and sexual transmission of the virus is inefficient, but occurs more frequently if the HCV-infected mother or sexual partner is also infected with human immunodeficiency virus type 1.

Most people with acute HCV infection are asymptomatic or have mild symptoms (fatigue, nausea, jaundice) but they are unable to clear the virus and in approximately 80% of cases this leads to chronic infection. In 15 to 20% of patients chronic HCV infection progresses at a variable rate to cirrhosis, with a 1 to 4% annual risk of developing hepatocellular carcinoma.

The discovery of HCV genome in 1989 by Choo et al, paved the way for the development of serological and molecular assays for viral hepatitis C. In the first generation of an enzyme-linked immunosorbent assay (ELISA), wells of microtitre plates were coated with purified recombinant antigen c100-3 which was derived from the non-structural 4 (NS4) region of the HCV genome. However, ELISA-1 was associated with a high percentage (50% to 70%) of false positive results among low-risk blood donors and in the presence of hyperglobulinemia. Thus, second-generation anti-HCV ELISAs were developed. ELISA-2 by Ortho Diagnostics contained recombinant antigens from the core (c22-3), NS3 region (c33c), and NS4 region (c100-3) as well as a part of c100-3, named 5-1-1. Third generation anti-HCV ELISA was introduced in Europe in 1993 and in the USA in 1996. In addition to the antigens of ELISA-2, thirdgeneration anti-HCV ELISA uses a NS5 region antigen of the viral genome. However, synthetic peptide antigens (c22 and c-100) replaced recombinant antigens of ELISA-2. Other manufactures, for example Abbott Diagnostics, used recombinant antigens derived from the same regions of HCV genome. Despite the increased sensitivity and specificity with each generation of ELISA, false-positive antibody results continue to be observed, particularly among low-risk blood donors. Thus, supplemental or confirmatory assays were developed in parallel with ELISA. The recombinant immunoblot assay (RIBA) was used extensively to confirm the presence or the absence of antibody to HCV epitopes. In RIBA, recombinant or peptide HCV antigens are blotted as separate bands onto a nitrocellulose strip flanked by a weak-positive (Level I) and a moderately positive (Level II) strip control.

Fig. 1 Genome organization of HCV and antigens licensed for diagnostic use



Since ELISA and RIBA are antibody tests, the positivity of either one or both does not necessarily indicate current HCV infection, as patients who have recovered from infection may remain anti-HCV positive for many years. Conversely, during seroconversion, antibody tests may be negative.

The direct molecular biology detection of HCV RNA by reverse-transcriptase polymerase chain reaction (RT-PCR) is considered the gold standard for the diagnosis of HCV infection.

INTENDED USE

HCV Real-TM Qual is a Real-Time test for the qualitative detection of Hepatitis C Virus in human plasma and simultaneous detection of a HCV-specific Internal Control (IC), by dual color detection.

PRINCIPLE OF ASSAY

HCV Real-TM Qual is a Real-Time test for the qualitative detection of Hepatitis C Virus in human plasma. HCV RNA is extracted from plasma, amplified using RT-amplification and detected using fluorescent reporter dye probes specific for HCV or HCV IC. HCV IC is an Internal Control and represents recombinant RNA-containing-structure which carried through all steps of analysis from nucleic acid extraction to PCR amplification-detection. Internal Control (IC) serves as an extraction and amplification control for each individually processed specimen and to identify possible reaction inhibition. IC is detected in a channel other than the HCV RNA.

Monitoring the fluorescence intensities during Real Time allows the detection of the accumulating product without having to re-open the reaction tube after the amplification.

MATERIALS PROVIDED

REF V1-100 FRT

HCV Real-TM Qual – PCR kit	Volume, ml	Quantity
HCV Positive Control (C+) ¹	0,06 ml	4 tubes
Negative Control (C–) ²	1,2 ml	4 tubes
HCV Internal Control IC-rec (IC) ³	0,28 ml	4 tubes
RT-G-mix-2	0,015 ml	4 tubes
RT-PCR-mix-1-TM	0,3 ml	4 tubes
RT-PCR-mix-2-TM	0,2 ml	4 tubes
Hot Start Taq Polymerase	0,02 ml	4 tubes
M-MLV Revertase	0,01 ml	4 tubes
TE-buffer⁴	1,2 ml	2 tubes
Standard HCV		
QS2 HCV ⁵	0,1 ml	4 tubes

must be used during the sample preparation procedure: add 90 μ l of C- (Neg. Control) and 10 μ l of C+ (HCV Positive Control-1) to the tube labeled Cpos; 1

2 must be used during the sample preparation procedure: add 100 µl of C- (Neg. Control) to the tube labeled Cneg;

add 10 µl of Internal Control during the RNA isolation procedure directly to the sample/lysis mixture; 3

4 5 must be used as Negative Control of Amplification;

must be used as Positive Control of Amplification.

REF TV1-100 FRT

HCV Real-TM Qual – PCR kit	Volume, ml	Quantity
HCV Positive Control (C+) ¹	0,06 ml	4 tubes
Negative Control (C–) ²	1,2 ml	4 tubes
HCV Internal Control IC-rec (IC) ³	0,28 ml	4 tubes
RT-G-mix-2	0,015 ml	4 tubes
RT-PCR-mix-1-TM	0,3 ml	4 tubes
RT-PCR-mix-2-TM	0,2 ml	4 tubes
Hot Start Taq Polymerase	0,02 ml	4 tubes
M-MLV Revertase	0,01 ml	4 tubes
TE-buffer ⁴	1,2 ml	2 tubes
Standard HCV		
• QS2 HCV ⁵	0,1 ml	4 tubes
Ribo-Sorb – Extraction kit	Volume, ml	Quantity
Lysis Solution	22.5	2 tubes
Washing Solution	20	2 tubes
Sorbent	1.25	2 tubes
RNA-eluent	0.5	10 tubes

¹ must be used during the sample preparation procedure: add 90 μl of C- (Neg. Control) and 10 μl of C+ (HCV Positive Control-1) to the tube labeled Cpos;

- 3 add 10 µl of Internal Control during the RNA isolation procedure directly to the sample/lysis mixture;
- 4 must be used as Negative Control of Amplification;
- 5 must be used as Positive Control of Amplification.

² must be used during the sample preparation procedure: add 100 μl of C- (Neg. Control) to the tube labeled Cneg;

HCV Real-TM Qual – PCR kit	Volume, ml	Quantity
HCV Positive Control (C+) ¹	0,06 ml	4 tubes
Negative Control (C–) ²	1,2 ml	4 tubes
HCV Internal Control IC-rec (IC) ³	0,28 ml	4 tubes
RT-G-mix-2	0,015 ml	4 tubes
RT-PCR-mix-1-TM	0,3 ml	4 tubes
RT-PCR-mix-2-TM	0,2 ml	4 tubes
Hot Start Taq Polymerase	0,02 ml	4 tubes
M-MLV Revertase	0,01 ml	4 tubes
TE-buffer ⁴	1,2 ml	2 tubes
Standard HCV		
QS2 HCV ⁵	0,1 ml	4 tubes
Ribo-Virus – Extraction kit	Volume, ml	Quantity
Buffer RAV1	35	2 tubes
Buffer RAW	30	2 tubes
Buffer RAV3 (concentrate)	12	2 tubes
Buffer RE	13	2 tubes
Rnase-free H₂O	13	2 tubes
Carrier RNA (lyophilized)	1 (mg)	2 tubes
Proteinase K	50 (mg)	2 tubes
Proteinase buffer	8	1 tube
Ribo Virus columns with collecting tubes (2ml)	/	100
Collecting tubes (2ml)	/	8 x 50

1 must be used during the sample preparation procedure: add 90 μl of C- (Neg. Control) and 10 μl of C+ (HCV Positive Control-1) to the tube labeled Cpos;

2 must be used during the sample preparation procedure: add 100 μl of C- (Neg. Control) to the tube labeled Cneg;

3 add 10 µl of Internal Control during the RNA isolation procedure directly to the sample/lysis mixture;

4 must be used as Negative Control of Amplification;

5 must be used as Positive Control of Amplification.

MATERIALS REQUIRED BUT NOT PROVIDED

- RNA isolation kit (only ref. V1-100FRT)
- Biological cabinet
- Desktop microcentrifuge for "eppendorf" type tubes (RCF max. 16,000 x g); Eppendorf 5415D or equivalent
- 60°C ± 2°C dry heat block
- Vortex mixer
- Pipettors (capacity 5-40 μl; 40-200 μl; 200-1000 μl) with aerosol barrier
- 1,5 ml polypropylene sterile tubes (Sarstedt, QSP, Eppendorf)
- Disposable gloves, powderless
- Tube racks
- Biohazard waste container
- 70% Ethanol (freshly prepared mixture of reagent grade 96% ethanol and distilled water)
- Acetone
- Refrigerator
- Real Time Thermal cycler
- Freezer

WARNINGS AND PRECAUTIONS

RUO

For Research Use Only

- 1. Lysis Solution contains guanidine thiocyanate. Guanidine thiocyanate is harmful if inhaled, or comes in contact with skin or if swallowed. Contact with acid releases toxic gas. (Xn: R: 20/21/22-36/37/38; S: 36/37/39) - (only ref. TV1-100FRT/N)
- 2. Wear disposable gloves, laboratory coats and eye protection when handling specimens and reagents. Thoroughly wash hands afterward.
- 3. Use routine laboratory precautions. Do not eat, drink, smoke, apply cosmetics, or handle contact lenses in laboratory work areas. Do not pipette by mouth.
- 4. Do not use a kit after its expiration date.
- 5. Do not mix reagents from different kits.
- 6. Dispose all specimens and unused reagents in accordance with local regulations.
- 7. Heparin has been shown to inhibit reaction. The use of heparinized specimens is not recommended.
- 8. Avoid repeated thawing and freezing of the reagents, this may reduce the sensitivity of the test.
- 9. Once the reagents have been thawed, vortex and centrifuge briefly the tubes.
- 10. Prepare quickly the Reaction mix.
- 11. Specimens may be infectious. Use Universal Precautions when performing the assay.
- 12. Specimens and controls should be prepared in a laminar flow hood.
- 13. Handle all materials containing specimens or controls according to Good Laboratory Practices in order to prevent cross-contamination of specimens or controls.
- 14. Clean and disinfect all spills of specimens or reagents using a disinfectant such as 0,5% sodium hypochlorite, or other suitable disinfectant. Follow by wiping down the surface with 70% ethanol.
- 15. Avoid contact of specimens and reagents with the skin, eyes and mucous membranes. If these solutions come into contact, rinse immediately with water and seek medical advice immediately.
- 16. Material Safety Data Sheets (MSDS) are available on request.
- 17. Use of this product should be limited to personnel trained in the techniques of amplification.
- 18. Workflow in the laboratory must proceed in a uni-directional manner, beginning in the Extraction Area and moving to the Amplification Area. Do not return samples, equipment and reagents in the area where you performed previous step. Personnel should be using proper anti-contamination safeguards when moving between areas.

STORAGE INSTRUCTIONS

HCV Real-TM Qual must be stored at temperature ≤ -20°C. The kit can be shipped at 2-8°C for 3-4 days but should be stored at temperature ≤ -20°C immediately on receipt.

STABILITY

HCV Real-TM Qual Test is stable up to the expiration date indicated on the kit label. The product will maintain performance through the control date printed on the label. Exposure to light, heat or humidity may affect the shelf life of some of the kit components and should be avoided. Repeated thawing and freezing of these reagents should be avoided, as this may reduce the sensitivity. Components stored under conditions other than those stated on the labels may not perform properly and may adversely affect the assay results.

Sacace[™] HCV Real-TM Qual New Version

SAMPLE COLLECTION, STORAGE AND TRANSPORT

Note: Handle all specimens as if they are potentially infectious agents.

- 1. EDTA tubes may be used with the **HCV Real-TM Qual**. Follow sample tube manufacturer's instructions.
- 2. Whole blood collected in EDTA should be separated into plasma and cellular components by centrifugation at 800-1600 x g for 20 min within six hours. The isolated plasma has to be transferred into a sterile polypropylene tube. Plasma may be stored at 2-8°C for an additional 3 days. Alternatively, plasma may be stored at -18°C for up to one month or 1 year when stored at -70°C.
- 3. Do not freeze whole blood.
- 4. Specimens anti-coagulated with heparin are unsuitable for this test.
- 5. Thaw frozen specimens at room temperature before using.
- 6. Whole blood must be transported at 2-25°C and processed within 6 hours of collection. Plasma may be transported at 2-8°C or frozen.
- 7. Transportation of clinical specimens must comply with country, federal, state and local regulations for the transport of etiologic agents.

RNA ISOLATION

The following isolation kits are recommended:

- \Rightarrow **DNA/RNA-Prep** (Sacace, REF K-2-9)
- \Rightarrow **Ribo Virus 100** spin column extraction kit (Sacace, REFK-2-C/100)
- \Rightarrow **Ribo-Sorb-100** (Sacace, REF K-2-1/100)
- \Rightarrow Magno Virus (Sacace, REF K-2-16/1000)
- ⇒ SaMag Viral Nucleic Acids Extraction kit (Sacace, REF SM003)

Please carry out the RNA extraction according to the manufacturer's instructions. Add 10 µl of Internal during the RNA isolation procedure directly to the sample/lysis mixture.

PCR PREPARATION

- 1. Thaw one set of reagents, vortex and centrifuge briefly the tubes.
- 2. Prepare requested quantity of reaction tubes
- 3. To prepare the **Reaction Mix** add the following reagents in a new sterile tube:
 - **10 μl** of **RT-PCR-mix-1**,
 - > 5 μl of RT-PCR-mix-2,
 - ➢ 0.25 µl of RT-G-mix-2
 - > 0.5 μl of Hot Start Taq Polymerase,
 - > 0.25 μl of M-MLV Revertase.

Vortex thoroughly and centrifuge briefly.

- 4. Add **15 μl** of **Reaction Mix** into each tube.
- 5. Add **10 µl** of **extracted RNA** sample to the appropriate tubes with Reaction Mix.

(If the Ribo-Sorb isolation kit is used as a RNA/DNA extraction kit, re-centrifuge all the tubes with extracted DNA for 2 min at maximum speed (12000-16000 g) and take carefully supernatant. N.B. don't disturb the pellet, sorbent inhibit reaction!).

- 6. Prepare for each run the following controls:
 - add 10 µl of QS2 HCV into the tube labelled PCR Positive Control HCV. Mix by pipetting;
 - add **10 µl** of **TE-buffer** to the tube labelled PCR Negative Control. Mix by pipetting;

Insert the tubes in the thermalcycler and program the instrument.

		Reaction volume (with allowance for one extra sample)				
Reagent volume for one reaction, µl		10.00 5.00 0.25 0.50 0.25			0.25	
Number of biological samples	Number of PCR reactions*	RT-PCR-mix-1	RT-PCR- mix-2	RT-G-mix-2	Hot Start Taq Polymerase	M-MLV Revertase
4	7	80	40	2.0	4.0	2.0
6	9	100	50	2.5	5.0	2.5
8	11	120	60	3.0	6.0	3.0
10	13	140	70	3.5	7.0	3.5
12	15	160	80	4.0	8.0	4.0
14	17	180	90	4.5	9.0	4.5
16	19	200	100	5.0	10.0	5.0
18	21	220	110	5.5	11.0	5.5
20	23	240	120	6.0	12.0	6.0
22	25	260	130	6.5	13.0	6.5
34	37	380	190	9.5	19.0	9.5
46	49	500	250	12.5	25.0	12.5

Table of Reaction Mix preparation

* Number of biological samples + 2 controls of extraction + 1 control of PCR.

Reverse transcription and Amplification

Create a temperature profile on your instrument as follows:

	Rotor-type Instruments ¹		Plate- or m	odular type Instrun	nents ²	
Step	<i>Temperature,</i> ℃	Time	Repeats	<i>Temperature,</i> ℃	Time	Repeats
1	50	15 min	1	50	15 min	1
2	95	15 min	1	95	15 min	1
	95	5 s		95	5 s	
3	60	20 s	5	60	20 s	5
	72	15 s		72	15 s	
	95	5 s		95	5 s	
4	60	20 s fluorescent signal detection	40	60	30 s fluorescent signal detection	40
	72	15 s		72	15 s	

¹ For example Rotor-Gene™ 3000/6000/Q (Corbett Research, Qiagen)

² For example, SaCycler-96™ (Sacace), CFX-96/iQ5™ (BioRad); Mx3000/3005P™ (Agilent), ABI® 7300/7500/StepOne Real Time PCR (Applied Biosystems), SmartCycler® (Cepheid)

Fluorescence is detected at the 4th step of Cycling 2 stage (60 °C) in FAM/Green and JOE/Yellow/Hex/Cy3 fluorescence channels.

Internal control is detected on the FAM (Green) channel, *HCV* RNA is detected on the JOE(Yellow)/HEX/Cy3 channel.

INSTRUMENT SETTINGS

Rotor-type instruments

Channel	Calibrate/Gain Optimisation	Threshold	More Settings/ Outlier Removal	Slope Correct
FAM/Green	from 5 FI to 10 FI	0.03	10 %	On
JOE/Yellow	from 5 FI to 10 FI	0.03	10 %	On

Plate-type instruments like SaCycler-96* (Sacace), CFX-96 / iQ5 (BioRad), ABI 7300/7500/StepOne (Applied Biosystem):

Channel	Threshold	
FAM	For each channel at a time set the threshold line at the level of 10-20 % of maximum fluorescence obtained for the Calibrator	
HEX	(QS1-HCV) in the last amplification cycle.	

* for SaCycler-96 instrument set "Criterion of the PCR positive result" to 70%, select "Multiplex Detection" as analysis type and "Threshold (Ct)" as Method.

SmartCycler (Cepheid):

Channel	Threshold
FAM	20
СуЗ	30

PROTOCOL AND DATA ANALYSIS:

Principle of interpretation is the following:

- The sample is considered **positive** for *HCV* RNA if the *Ct* value detected in the channel for the JOE/Yellow fluorophore does not exceed the boundary value specified in the table.
- The sample is considered **negative** for *HCV* RNA if the *Ct* value in the channel for the JOE/Yellow fluorophore is absent or if the *Ct* value detected in the channel for the JOE/Yellow fluorophore is greater than the specified boundary value and the *Ct* value in the channel for the FAM fluorophore does not exceed the boundary value specified in the table.
- The sample is considered **invalid** if an equivocal result (Ct value for Internal Control > boundary value or absent) is obtained in any of the channels. In this case, analysis of this sample should be repeated once again starting from the extraction.

	Channel for	Ct boundary value		
Sample/Control	fluorophore	Rotor-type instruments	Plate-type instruments	
C.	FAM/Green	27	29	
C+	JOE/Yellow/Hex/Cy3	28	32	
QS2 HCV	FAM/Green	30	32	
	JOE/Yellow/Hex/Cy3	28	32	
Clinical complex	FAM/Green	27	29	
Clinical samples	JOE/Yellow/Hex/Cy3	35	35	
C-	FAM/Green	27	29	

Boundary value of the cycle threshold, Ct

The result of the analysis is considered reliable only if the results obtained for Positive and Negative Controls of amplification as well as for the Positive and Negative Control of extraction are correct (see table: Results for controls).

Results for controls

Control	Stage for control	Ct value in the chanr	nel for fluorophore
Control	Stage for control	FAM	JOE
C–	RNA extraction	≤boundary value	Absent
PCE (C+)	RNA extraction	≤boundary value	≤boundary value
NCA	Amplification	Absent	Absent
QS2 HCV	Amplification	≤boundary value	≤boundary value

QUALITY CONTROL PROCEDURE

A defined quantity of Internal Control (IC) is introduced into each sample and control at the beginning of sample preparation procedure in order to control the extraction process of each individual sample and to identify possible reaction inhibition.

A negative control of extraction (NCE), negative amplification control (NCA), positive control of extraction (C+), positive amplification control (QS2 HCV) are required for every run to verify that the specimen preparation, the amplification and the detection steps are performed correctly.

If the controls are out of their expected range (see table Results for Controls), all of the specimens and controls from that run must be processed beginning from the sample preparation step.

PERFORMANCE CHARACTERISTICS

Analytical specificity

The analytical specificity of **HCV Real-TM Qual** PCR kit is ensured by selection of specific primers and probes and stringent reaction conditions. The primers and probes were tested for possible homologies to all sequences deposited in gene banks by sequence comparison analysis as well as with genomic DNA/RNA of the following organisms and viruses: hepatitis A virus; hepatitis B virus; hepatitis D virus; human immunodeficiency virus; cytomegalovirus; Epstein-Barr virus; herpes simplex virus types 1 and 2; *varicella-zoster* virus; human herpes virus types 6 and 8; parvovirus B19; tick-borne encephalitis virus; West Nile encephalitis; adenovirus types 2, 3, and 7; *Escherichia coli*; *Staphylococcus aureus; Streptococcus pyogenes, S.agalactiae;* and *Homo sapiens*. Cross-reactions for the above-mentioned organisms and viruses have not been detected.

Analytical sensitivity

The kit **HCV Real-TM Qual** allows to detect HCV RNA in 100% of the tests with a sensitivity specified in the table below:

Volume of sample for extraction, µl	RNA/DNA extraction kit	Analytical sensitivity, IU/ml
100	RIBO-sorb	100
200	Magno-Virus	50
1000	Magno-Virus	10

TROUBLESHOOTING

- 1. Weak (Ct > boundary value) signal of the IC (Fam/Green channel): retesting of the sample is required.
 - The PCR was inhibited.
 - $\Rightarrow\,$ Make sure that you use a recommended RNA extraction method and follow the manufacturer's instructions.
 - The reagents storage conditions didn't comply with the instructions.
 - \Rightarrow Check the storage conditions
 - The PCR conditions didn't comply with the instructions.
 - \Rightarrow Check the PCR conditions and for the IC detection select the fluorescence channel reported in the protocol.
 - The IC was not added to the sample during the pipetting of reagents.
 - \Rightarrow Make attention during the RNA extraction procedure.
- 2. Any signal on the Joe/HEX/Cy3 channel with Negative Control of extraction (C-).
 - Contamination during RNA extraction procedure. All samples results are invalid.
 - \Rightarrow Decontaminate all surfaces and instruments with sodium hypochlorite and ethanol.
 - \Rightarrow Use only filter tips during the extraction procedure. Change tips among tubes.
 - \Rightarrow Repeat the RNA extraction with the new set of reagents.
- 3. Any signal with Negative PCR Control (NCA).
 - Contamination during PCR preparation procedure. All samples results are invalid.
 - ⇒ Decontaminate all surfaces and instruments with sodium hypochlorite and ethanol or special DNA decontamination reagents.
 - \Rightarrow Pipette the Positive controls at the end.
 - \Rightarrow Repeat the PCR preparation with the new set of reagents.

EXPLANATION OF SYMBOLS



Catalogue Number



For Research Use Only



Lot Number



Expiration Date



Contains reagents



Caution!



Version



Manufacturer



Temperature limitation

- *SaCycler® is trademarks of Sacace Biotechnologies *CFX-96™ and iQ5™ are trademarks of Bio-Rad Laboratories * Rotor-Gene™ Technology is a registered trademark of Corbett Research
- *MX3000P® and MX3005P® are trademarks of Stratagene

*Applied Biosystems® is trademarks of Applera Corporation * SmartCycler® is a registered trademark of Cepheid



Sacace Biotechnologies Srl via Scalabrini, 44 – 22100 – Como – Italy Tel +390314892927 Fax +390314892926 mail: info@sacace.com web: www.sacace.com